A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 45/00 (2006.01) A61K 38/00 (2006.01) A61K 39/00 (2006.01) A61P 25/00 (2006.01) C12Q 1/48 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2474689
It is intended to provide: a method of ameliorating circadian rhythm disorder characterized by inhibiting the phosphorylation of BMAL1 by JNK3due to the interaction between c-Jun N-terminal kinase 3 (JNK3) and BMAL1; a method of preventing and/or treating diseases caused by circadian rhythm disorder; and a method of identifying a compound inhibiting the phosphorylation of BMAL1 by JNK3. It is also intended to provide: a remedy for circadian rhythm disorder having the above characteristic; a preventive and/or a remedy for diseases caused by circadian rhythm disorder; a compound obtained by the identification method as described above; an inhibitor for the BMAL1 phosphorylation by JNK3 comprising the above compound; a transcriptional activity regulatory releaser/ phosphorylation inhibitor for a BMAL1-CLOCK complex which comprises a JNK3 expression and/or function inhibitor; and medicinal compositions comprising one of them.
L'invention concerne une méthode permettant d'améliorer les troubles du rythme circadien. Cette méthode se caractérise par l'inhibition de la phosphorylation de BMAL1 par JNK3 résultant de l'interaction entre la kinase JNK3 (c-Jun N-terminal kinase 3) et BMAL1, une méthode de prévention et/ou de traitement des pathologies causées par les troubles du rythme circadien, et un procédé permettant d'identifier un composant inhibant la phosphorylation de BMAL1 par JNK3. L'invention concerne en outre un médicament permettant de traiter les troubles du rythme circadien, ce médicament présentant les caractéristiques décrites ci-dessus, un médicament destiné à prévenir et/ou à traiter les pathologies causées par les troubles du rythme circadien, un composé obtenu au moyen du procédé d'identification décrite, un inhibiteur de la phosphorylation de BMAL1 par JNK3 comprenant le composé décrit, un agent régulateur de l'activité transcriptionnelle/inhibiteur de la phosphorylation du complexe BMAL1/CLOCK comprenant une expression de JNK3 et/ou un inhibiteur fonctionnel, et des compositions thérapeutiques comprenant l'un de ces composants.
Doi Hirofumi
Wada Naoya
Celestar Lexico-Sciences Inc.
Daiichi Pharmaceutical Co. Ltd.
Moffat & Co.
LandOfFree
Drugs ameliorating circadian rhythum disorder does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drugs ameliorating circadian rhythum disorder, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drugs ameliorating circadian rhythum disorder will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1590966